TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04117971

Intervention type: OTHER
Intervention: Questionnaire
Description: The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.

Intervention type: OTHER
Intervention: Questionnaire
Description: The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.

Intervention type: OTHER
Intervention: Questionnaire
Description: The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
Study: NCT00322283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oglemilast
Description: Oglemilast, 15mg once per day, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-marched placebo, once per day, oral administration
Study: NCT00801177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 6~1000 mg I.V.
Study: NCT02253862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: administered days 1, 8 and 16
Study: NCT03560856

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant + palbociclib
Description: Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
Study: NCT00751595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tat protein
Description: Biologically active recombinant Tat protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tat protein
Description: Biologically active recombinant Tat protein
Study: NCT03501667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of decision support tool
Description: use of a decision support software during clinical assessment of a case

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of UpToDate
Description: Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
Study: NCT02410304

Intervention type: DEVICE
Group type: OTHER
Intervention: Xrays
Description: Clinical evaluation

Intervention type: DEVICE
Group type: OTHER
Intervention: Xrays
Description: Clinical evaluation

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound (B mode )

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound (D mode)
Study: NCT03092102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
Study: NCT02193399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy in patients with stem cell transplantation
Description: The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient.
Study: NCT02011659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Study: NCT03894670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard mixed breakfast meal
Description: The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SmartBar™
Description: SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
Study: NCT01155362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001 Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001 Intravenous Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001 Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehice Control
Study: NCT03366298

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epipen 0.3mg
Description: Epipen 0.3mg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epipen 0.3mg
Description: Epipen 0.3mg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epipen 0.3mg
Description: Epipen 0.3mg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epipen 0.3mg
Description: Epipen 0.3mg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 300mcg
Description: Emerade 300mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 300mcg
Description: Emerade 300mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 300mcg
Description: Emerade 300mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 300mcg
Description: Emerade 300mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 500mcg
Description: Emerade 500mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 500mcg
Description: Emerade 500mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 500mcg
Description: Emerade 500mcg auto-injector

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Emerade 500mcg
Description: Emerade 500mcg auto-injector
Study: NCT00268489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT04389021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol.
Study: NCT03095794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: How people learn another's value preference during decision under risk
Description: The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mechanism of making a group decision under risk that influences on in-group members
Description: how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mechanism of making a group decision that influences on out-group members
Description: Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
Study: NCT02025868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence reinforcement
Description: Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
Description: Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
Study: NCT03008642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-Rebreathing technique at diagnosis of polycythemia
Description: The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
Study: NCT02230059

Intervention type: OTHER
Intervention: No Intervention
Description: Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
Study: NCT00736255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lis-dexamphetamine (Vyvanse)
Description: Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
Study: NCT00633906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HORIZONS HIV Intervention
Description: Two-session, group-based interactive HIV prevention intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: enhanced standard-of-care
Description: 1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
Study: NCT04125550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
Study: NCT03652038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8236
Description: Study drug to be administered via inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8236
Description: Study drug to be administered via inhaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8236
Description: Study drug to be administered via inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered via inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered via inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered via inhaler device
Study: NCT00407095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12-42 mg/day
Study: NCT01781715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting coronary stent
Description: Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting coronary stent
Description: Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
Study: NCT04058340

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactizole nebulization
Description: Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactizole nebulization
Description: Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution in nebulization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution in nebulization
Study: NCT04225130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy -for Suicide
Description: The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
Study: NCT01439282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
Study: NCT01141504

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeakATP 250
Description: The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that are comparable in size and color to the active comparator for blinding purposes

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeakATP 400
Description: The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PeakATP 400 plus proprietary blend
Description: The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
Study: NCT00350948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcyta
Description: Day 1 of 28 day Cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: Day 1 of 28 Day Cycle. 50 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Day 1 of 28 Day Cycle. 50 mg/m2
Study: NCT01834092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: 2 Units of plasma transfused equvilant to 2 times 275ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma
Description: 2 Units of plasma transfused equvilant to 2 times 275ml
Study: NCT03045770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium levofolinate
Description: Calcium levofolinate was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium levofolinate
Description: Calcium levofolinate was used as first line treatment with AGC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium levofolinate
Description: Calcium levofolinate was used as first line treatment with AGC.
Study: NCT01502709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Neurostimulation
Description: 1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo device
Study: NCT04389762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily ingestion of Lactobacillus plantarum PS128
Description: daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
Study: NCT00732511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol extended release
Description: tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
Study: NCT00075400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00346073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL®
Description: Sanofi Pasteur
Study: NCT02195024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI group
Description: • All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange